Table 1 Demographics and baseline characteristics.
Patient characteristics | Dose-escalation cohort (n = 19) | Dose-expansion cohort (n = 24) |
|---|---|---|
Median Age, y (range) | 62 (26, 74) | 60 (27, 79) |
Gender, n (%) | ||
 Female | 13 (68.4%) | 12 (50%) |
 Male | 6 (31.6%) | 12 (50%) |
Race, n (%) | ||
 Asian | 0 (0%) | 1 (4.2%) |
 White | 19 (100%) | 22 (91.7%) |
 Uknown | 0 (0%) | 1 (4.2%) |
ECOG performance status, n (%) | ||
 0 | 6 (31.6%) | 10 (41.7%) |
 1 | 14 (68.4%) | 14 (58.3%) |
Prior Gemcitabine Therapy, n (%) | ||
 Yes | 7 (36.8%) | 12 (50%) |
 No | 12 (63.2%) | 12 (50%) |
Tumor Type, n (%) | ||
 Lung | 6 (32%) | 5 (21%) |
 Pancreas | 5 (26%) | 7 (29%) |
 Cholangiocarcinoma | 1 (5.2%) | 0 |
 Hepatobiliary | 1 (5.2%) | 2 (8%) |
 Breast | 1 (5.2%) | 2 (8%) |
 Ovary | 1 (5.2%) | 2 (8%) |
 Uterine Carcinoma | 1 (5.2%) | 0 |
 Head and Neck | 1 (5.2%) | 0 |
 Melanoma | 1 (5.2%) | 0 |
 Sarcoma | 1 (5.2%) | 0 |
 Thorax | 0 | 1 (4.2%) |
 Small Bowel | 0 | 1 (4.2%) |
 Pelvis | 0 | 1 (4.2%) |
 Cervix | 0 | 1 (4.2%) |
 Nerve Sheath Tumor | 0 | 1 (4.2%) |
 Unknown Primary | 0 | 1 (4.2%) |
